CoChat

Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study

Open access
Tartof, Sara Y, Slezak, Jeff M, Puzniak, Laura, Hong, Vennis, Xie, Fagen, Ackerson, Bradley K, Valluri, Srinivas R, Jodar, Luis, McLaughlin, John M · 2022 · The Lancet Respiratory Medicine
Cited by 140

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background The duration of protection against the omicron (B.1.1.529) variant for current COVID-19 vaccines is not well characterised. Vaccine-specific estimates are especially needed. We aimed to evaluate the effectiveness and durability of two and three doses of the BNT162b2 (Pfizer–BioNTech) mRNA vaccine against hospital and emergency department admissions due to the delta (B.1.617.2) and omicron variants. Methods In this case–control study with a test-negative design, we analysed electronic health records of members of Kaiser Permanente Southern California (KPSC), a large integrated health system in California, USA, from Dec 1, 2021, to Feb 6, 2022. Vaccine effectiveness was calculated in KPSC patients aged 18 years and older admitted to hospital or an emergency department (without a subsequent hospital admission) with a diagnosis of acute respiratory infection and tested for SARS-CoV-2 via PCR. Adjusted vaccine effectiveness was estimated with odds ratios from adjusted logistic regression models. This study is registered with ClinicalTrials.gov (NCT04848584). Findings Analyses were done for 11 123 hospital or emergency department admissions. In adjusted analyses, effectiveness of two doses of the BNT162b2 vaccine against the omicron variant was 41% (95% CI 21–55) against hospital admission and 31% (16–43) against emergency department admission at 9 months or longer after the second dose. After three doses, effectiveness of BNT162b2 against hospital admission due to the omicron variant was 85% (95% CI 80–89) at less than 3 months but fell to 55% (28–71) at 3 months or longer, although confidence intervals were wide for the latter estimate. Against emergency department admission, the effectiveness of three doses of BNT162b2 against the omicron variant was 77% (72–81) at less than 3 months but fell to 53% (36–66) at 3 months or longer. Trends in waning against SARS-CoV-2 outcomes due to the delta variant were generally similar, but with higher effectiveness estimates at each timepoint than those seen for the omicron variant. Interpretation Three doses of BNT162b2 conferred high protection against hospital and emergency department admission due to both the delta and omicron variants in the first 3 months after vaccination. However, 3 months after receipt of a third dose, waning was apparent against SARS-CoV-2 outcomes due to the omicron variant, including hospital admission. Additional doses of current, adapted, or novel COVD-19 vaccines might be needed to maintain high levels of protection against subsequent waves of SARS-CoV-2 caused by the omicron variant or future variants with similar escape potential. Funding Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(22)00101-1

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 28

  1. Viana, 2022, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa, Nature, 603, 679, 10.1038/s41586-022-04411-y · DOI · Paper page
  2. Cele, 2022, Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization, Nature, 602, 654, 10.1038/s41586-021-04387-1 · doi:10.1038/s41586-021-04387-1 · Paper page
  3. Nemet, 2022, Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection, N Engl J Med, 386, 492, 10.1056/NEJMc2119358 · DOI · Paper page
  4. De Marco, 2021, Preserved T cell reactivity to the SARS-CoV-2 Omicron variant indicates continued protection in vaccinated individuals, bioRxiv
  5. GeurtsvanKessel, 2022, Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients, Sci Immunol, 7, 10.1126/sciimmunol.abo2202 · DOI · Paper page
  6. Liu, 2022, Vaccines elicit highly cross-reactive cellular immunity to the SARS-CoV-2 omicron variant, medRxiv
  7. Keeton, 2022, T cell responses to SARS-CoV-2 spike cross-recognize Omicron, Nature, 603, 488, 10.1038/s41586-022-04460-3 · DOI · Paper page
  8. Danza, 2022, SARS-CoV-2 infection and hospitalization among adults aged ≥18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (omicron) variant predominance — Los Angeles County, California, November 7, 2021–January 8, 2022, MMWR Morb Mortal Wkly Rep, 71, 177, 10.15585/mmwr.mm7105e1 · DOI
  9. Buchan, 2022, Effectiveness of COVID-19 vaccines against Omicron or Delta infection, medRxiv
  10. Chemaitelly, 2022, Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar, medRxiv
  11. Andrews, 2022, Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N Engl J Med, 10.1056/NEJMoa2119451 · doi:10.1056/nejmoa2119451 · Paper page
  12. Koebnick, 2012, Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data, Perm J, 16, 37, 10.7812/TPP/12-031 · DOI · Paper page
  13. Scott, 2021, Track Omicron's spread with molecular data, Science, 374, 1454, 10.1126/science.abn4543 · DOI · Paper page
  14. Turner, 2021, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses, Nature, 596, 109, 10.1038/s41586-021-03738-2 · DOI · Paper page
  15. Arunachalam, 2021, Systems vaccinology of the BNT162b2 mRNA vaccine in humans, Nature, 596, 410, 10.1038/s41586-021-03791-x · DOI · Paper page
  16. Teijaro, 2021, COVID-19 vaccines: modes of immune activation and future challenges, Nat Rev Immunol, 21, 195, 10.1038/s41577-021-00526-x · DOI · Paper page
  17. Bruxvoort, 2021, Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults, J Infect Dis
  18. Pozzetto, 2021, Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination, Nature, 600, 701, 10.1038/s41586-021-04120-y · DOI · Paper page
  19. Parry, 2021, Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people, Immun Ageing, 18, 34, 10.1186/s12979-021-00246-9 · DOI
  20. Liu, 2021, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial, Lancet, 398, 856, 10.1016/S0140-6736(21)01694-9 · DOI · Paper page
  21. Munro, 2021, Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial, Lancet, 398, 2258, 10.1016/S0140-6736(21)02717-3 · DOI · Paper page
  22. Atmar, 2022, Homologous and heterologous Covid-19 booster vaccinations, N Engl J Med, 386, 1046, 10.1056/NEJMoa2116414 · DOI · Paper page
  23. GeurtsvanKessel, 2022, Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients, Sci Immunol, 10.1126/sciimmunol.abo2202 · DOI · Paper page
  24. Bar-On, 2022, Protection by 4th dose of BNT162b2 against Omicron in Israel, medRxiv
  25. De Serres, 2013, The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials, Euro Surveill, 18, 10.2807/1560-7917.ES2013.18.37.20585 · DOI · Paper page
  26. Haber, 2015, A probability model for evaluating the bias and precision of influenza vaccine effectiveness estimates from case-control studies, Epidemiol Infect, 143, 1417, 10.1017/S0950268814002179 · DOI
  27. Lipsitch, 2016, Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies, Int J Epidemiol, 45, 2060
  28. Iuliano, 2022, Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020-January 2022, MMWR Morb Mortal Wkly Rep, 71, 146, 10.15585/mmwr.mm7104e4 · DOI · Paper page

Cited by

See all 140

Metadata

Authors
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M.
Venue
The Lancet Respiratory Medicine
Publisher
Elsevier BV
Published
2022-07
Volume
10
Issue
7
Pages
689-699
ISSN
2213-2600 (ISSN-L)
OpenAlex
W4224233017
Cited by
140
References
17
FWCI
14.97
Type
journal article
Language
en
Open access
green
Funders
  • Pfizer Inc Boulder
  • Pfizer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. https://app.cochat.ai/papers/10.1016/s2213-2600(22)00101-1
The paper
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2022). Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(22)00101-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.